<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251770</url>
  </required_header>
  <id_info>
    <org_study_id>HGNPE-15-2010</org_study_id>
    <nct_id>NCT01251770</nct_id>
  </id_info>
  <brief_title>Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children</brief_title>
  <acronym>surgical-Na</acronym>
  <official_title>Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Niños Pedro de Elizalde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Niños Pedro de Elizalde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the blood sodium level after 12 hours
      following the initiation of therapy with either 0.3% NaCl/dextrose 5% or 0.45% NaCl/dextrose
      5%, in postsurgical hospitalized children requiring maintenance IV fluid administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Despite prescription of maintenance IV fluids in hospitalized children is widely
      used since 1957 (Holiday &amp; Segar), it is not always adequate for children with acute
      diseases, leading to hyponatremia. This mainly occurs due to a non-physiologic ADH secretion
      in this group of patients due to nausea, stress, pain, and surgical interventions, and the
      use of hypotonic maintenance IV fluids.

      0.3% NaCl/dextrose 5%, is widely use as IV maintenance fluid in children after surgery. There
      is evidence suggesting that these IV fluids used in postsurgical hospitalized patients do not
      provide the adequate amount of sodium they require, leading to an increased risk of
      developing hyponatremia. Using 0.45% NaCl/dextrose 5% as IV maintenance fluid in these
      children would prevent hyponatremia, but this treatment has not been totally studied yet.

      Study procedures: Hospitalized children who fulfill inclusion criteria and not having any of
      the exclusion criteria will be considered for the enrolment after written informed consent.

      Venous blood samples will be taken at enrollment (baseline) for estimation of serum sodium.
      After randomization, one group will receive 0.3% NaCl/dextrose 5%, IV, at standard
      maintenance rate (100 ml/kg for the first 10 kg of body weight, 50 ml/kg for the next 10 kg,
      and 20 ml/kg for body weight exceeding 20 kg). The second group will receive 0.45%
      NaCl/dextrose 5%, IV, at the same rate.

      Serum sodium will be estimated in both groups after 12 hours of intravenous fluid therapy.

      Children who required oral fluids will be excluded from per-protocol analysis, and only
      analyzed for intention to treat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sodium Levels</measure>
    <time_frame>Change from baseline in sodium level after 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IV Fluid Intake</measure>
    <time_frame>12 hours from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>half saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>third saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45% NaCl/dextrose 5%</intervention_name>
    <description>Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 body surface.</description>
    <arm_group_label>half saline</arm_group_label>
    <other_name>half saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% NaCl/dextrose 5%</intervention_name>
    <description>Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 surface.</description>
    <arm_group_label>third saline</arm_group_label>
    <other_name>third saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postsurgical children admitted to HGNPE Department of Surgery between january 2010 and
             october 2011.

        Aged 1 month to 16 years. Initial plasma Na between 135-145 mmol/L. Primary route of fluid
        administration is anticipated to be intravenous, in the first 12 hours following surgery.

        Informed consent of parent/guardian.

        Exclusion Criteria:

          -  • Children with illness that have primary fluid and electrolyte imbalance such as:

               -  Shock: Defined as acute circulatory failure resulting in decreased tissue
                  perfusion and manifesting as altered sensorium, hypothermia (&lt;35oC), tachycardia,
                  prolonged capillary filling time (&gt;3 seconds), hypotension (BP &lt; 5th percentile
                  for age), oliguria (&lt;0.5 ml/kg/hr), hypoxemia, hyperlactatemia, requirement of
                  fluid bolus and/ or vasopressors.

               -  Diarrhea and Dehydration: Children presenting with diarrhea and features of
                  dehydration: lethargy, irritability and altered sensorium, thirst, decreased
                  urine output, sunken eyes &amp; dry mucous membranes, loss of skin elasticity.;
                  children with ongoing diarrhea will be excluded even if there is no dehydration.

               -  Fluid Overload: Cirrhosis, Congestive heart failure, Acute and Chronic renal
                  failure, Nephrotic syndrome.

                    -  Hyperglycemia: blood glucose &gt; 180 mg/ dl.

                    -  Require ICU admission.

                    -  Severe Protein Energy Malnutrition: Defined as grade III (50-59% of expected
                       weight for age) and grade IV (less than 50% of expected weight for age) as
                       per IAP classification.

                    -  Patients in whom either hypotonic or isotonic solutions may be
                       contraindicated/necessary: i.e. specific neurosurgical patients (ie those at
                       risk of increased ICP, e.g. requiring actual brain surgery, ICP monitor or
                       external ventricular drain insertion), patients with diabetic ketoacidosis,
                       acute (≤ 7 days) burns, pre-existing CHF, liver failure or cirrhosis, renal
                       failure.

                    -  Patients with known pre-existing risk of PNa derangements: DI or SIADH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Dicembrino, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Niños Pedro de Elizalde</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Niños Pedro de Elizalde</name>
      <address>
        <city>Buenos Aires</city>
        <state>CF</state>
        <zip>C1270AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17981159</url>
    <description>Hyponatremia treatment guidelines 2007: expert panel recommendations</description>
  </link>
  <reference>
    <citation>Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child. 2006 Oct;91(10):828-35. Epub 2006 Jun 5. Review.</citation>
    <PMID>16754657</PMID>
  </reference>
  <reference>
    <citation>Neville KA, Sandeman DJ, Rubinstein A, Henry GM, McGlynn M, Walker JL. Prevention of hyponatremia during maintenance intravenous fluid administration: a prospective randomized study of fluid type versus fluid rate. J Pediatr. 2010 Feb;156(2):313-9.e1-2. doi: 10.1016/j.jpeds.2009.07.059. Epub 2009 Oct 9.</citation>
    <PMID>19818450</PMID>
  </reference>
  <reference>
    <citation>Yung M, Keeley S. Randomised controlled trial of intravenous maintenance fluids. J Paediatr Child Health. 2009 Jan-Feb;45(1-2):9-14. Epub 2007 Nov 25.</citation>
    <PMID>18036144</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>December 13, 2011</results_first_submitted>
  <results_first_submitted_qc>December 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2012</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyponatremia</keyword>
  <keyword>Water-Electrolyte Imbalance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ClNa 0.3%</title>
          <description>maintenance solution with ClNa 0.3%</description>
        </group>
        <group group_id="P2">
          <title>ClNa 0.45%</title>
          <description>maintenance solution with ClNa 0.45%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ClNa 0.3%</title>
          <description>maintenance solution with ClNa 0.3%</description>
        </group>
        <group group_id="B2">
          <title>ClNa 0.45%</title>
          <description>maintenance solution with ClNa 0.45%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.6" spread="35.1"/>
                    <measurement group_id="B2" value="94.4" spread="42.2"/>
                    <measurement group_id="B3" value="100.5" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Sodium Levels</title>
        <time_frame>Change from baseline in sodium level after 12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ClNa 0.3%</title>
            <description>maintenance solution with ClNa 0.3%</description>
          </group>
          <group group_id="O2">
            <title>ClNa 0.45%</title>
            <description>maintenance solution with ClNa 0.45%</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sodium Levels</title>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Natremia baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.9" spread="3.4"/>
                    <measurement group_id="O2" value="138.1" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Natremia at 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.1" spread="3.4"/>
                    <measurement group_id="O2" value="138.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Sodium difference at the beginning</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serum Sodium at the end of the study</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.871</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IV Fluid Intake</title>
        <time_frame>12 hours from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ClNa 0.3%</title>
            <description>maintenance solution with ClNa 0.3%</description>
          </group>
          <group group_id="O2">
            <title>ClNa 0.45%</title>
            <description>maintenance solution with ClNa 0.45%</description>
          </group>
        </group_list>
        <measure>
          <title>IV Fluid Intake</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1434" spread="444"/>
                    <measurement group_id="O2" value="1448" spread="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.895</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>until hospital discharge, average 5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ClNa 0.3%</title>
          <description>maintenance solution with ClNa 0.3%</description>
        </group>
        <group group_id="E2">
          <title>ClNa 0.45%</title>
          <description>maintenance solution with ClNa 0.45%</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervous system disorders</sub_title>
                <description>seizures, coma, headache.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <description>serum sodium between 130-134.9 meq/L</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <description>serum sodium more than 145 mEq/L</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Facundo Jorro Barón</name_or_title>
      <organization>Hospital General de Niños Pedro de Elizalde</organization>
      <phone>00541143632100 ext 2035</phone>
      <email>jorrobox@yahoo.com.ar</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

